Sugi Predict

Sugi Predict / Compounds / SCHEMBL21069640

SCHEMBL21069640

SCHEMBL21069640

CC(C)(C)OC(=O)NCCOCCOCCOCCOCCOCC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ GAA P10253 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.47
▸ IDO1 P14902 1/20 0.44
▸ CA12 O43570 3/20 0.43
▸ CA1 P00915 3/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA9 Q16790 3/20 0.43
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ SUCNR1 Q9BXA5 2/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ BCHE P06276 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ADRB2 P07550 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ GBA1 P04062 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699512 1.00 MEN1 (0.49) MEN1KMT2AGAATDP1IDO1
SCHEMBL21071644 1.00 MEN1 (0.49) MEN1KMT2AGAATDP1IDO1
SCHEMBL1261192 1.00 MEN1 (0.49) MEN1KMT2AGAATDP1IDO1
SCHEMBL3617073 1.00 MEN1 (0.49) MEN1KMT2AGAATDP1IDO1
SCHEMBL25695638 1.00 MEN1 (0.49) MEN1KMT2AGAATDP1IDO1
SCHEMBL23728812 1.00 MEN1 (0.49) MEN1KMT2AGAATDP1IDO1
SCHEMBL320644 0.97 MEN1 (0.51) MEN1KMT2AGAATDP1IDO1
SCHEMBL25194819 0.95 MEN1 (0.49) MEN1KMT2AGAATDP1IDO1
SCHEMBL13137474 0.94 MEN1 (0.44) MEN1KMT2AGAATDP1IDO1
SCHEMBL14264537 0.94 MEN1 (0.44) MEN1KMT2AGAATDP1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250032625-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS Merck Patent KGaA (DE) 2025-01-30 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
EP-4426700-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS Merck Patent GmbH (DE) 2024-09-11 — — EP disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-20220062258-A1 Heterocyclic derivatives MERCK PATENT GMBH (DE) 2022-03-03 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
WO-2020152067-A1 HETEROCYCLIC DERIVATIVES MERCK PATENT GMBH (DE) 2020-07-30 — — WO disclosed
WO-2019183523-A1 HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) GENENTECH, INC. (US) 2019-09-26 — — WO disclosed
WO-2019183523-A1 HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) GENENTECH, INC. (US) 2019-09-26 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885
US-20250032625-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS TEAD1, UBQLN1, TTI1 MEN1 3500/4885KMT2A 3068/4885GAA 401/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885
US-20220062258-A1 Heterocyclic derivatives XIAP, UBQLN1, UBQLN2 MEN1 2341/4885KMT2A 1225/4885GAA 3870/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885GAA 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.